NCT00362635

Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

A Double-blinded and Randomised Study to Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 92 (estimated)
• Sponsor: Bukwang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the efficacy and safety of 48-week treatment with Clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection.

Conditions

• Hepatitis B

Interventions

Type	Name	Description
DRUG	Clevudine

Timeline

• Start date: 2006-08-01
• Primary completion: 2011-12-01
• First posted: 2006-08-10
• Last updated: 2012-07-26

Locations

2 sites across 1 country: Hong Kong